By studying drugs that have been withdrawn from the market for safety reasons, we can gain valuable insight into postmarketing surveillance as well as the process for approving new drugs. In the past decade there has been a major shift in the funding structure of the Therapeutic Products Directorate
No takes yet. Share an insight, caveat, or question.
Joel Lexchin (2005) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: